GNRH1 and Stroke: Similarly, IHD, stroke, or CHF were observed in a significantly lower proportion of patients from the GnRH antagonist-treated group than the GnRHa-treated group (3.6% vs 11.6% respectively; p < 0.0001) and across both groups with pre-existing CVD (1.8% vs 12.3% respectively; p < 0.0001) and no pre-existing CVD (4.5% vs 11.4% respectively; p < 0.0001; Table 2).